Builders FirstSource, Inc.
BLDR is a cyclical compounder trading from a deeply reset price, with earnings depressed by housing softness and specialty margin pressure, but the current setup already discounts much of that while cost actions, buybacks, and eventual housing normalization can lift earnings power materially above FY2025.
BLDR is being priced like a business with no credible recovery path. That goes too far. At $74.54, the stock reflects a sharp de-rating after a real earnings reset, with shares 50.6% below the 52-week high and 25.4% below the 200-day average. The underlying business is clearly under pressure, but it is not broken. BLDR still generated $15.2B of FY2025 revenue, remains profitable at an 8.7% operating margin, and is guiding to $1.1B-$1.5B of FY26 adjusted EBITDA even after cutting outlook. For a company with scale, value-added manufacturing, installed capabilities, and ongoing share gains in single-family, that setup is more trough-like than terminal.
The case depends on three things. First, margins need to stop falling. Q1's 5.0% EBITDA margin was weak, with gross margin down 220 bps, but management has already launched $100M of cost actions and realized $13M in Q1. Second, BLDR needs to keep taking share where demand still exists. Management said single-family share growth continued even as macro conditions worsened, which matters because it shows BLDR's operating model is still winning accounts in a shrinking market. Third, capital allocation has to stay disciplined enough to turn cyclical weakness into per-share upside. Repurchasing 3.3M shares for $303M at depressed prices helps, but only if leverage remains manageable.
What the market may be missing is the gap between current earnings and normalized earnings power. The headline 28.21x P/E looks expensive, but that is a bad lens when FY2025 EPS dropped 31.7% and margin pressure is still moving through the model. On sales, the stock is at just 0.55x, far below the peer average 2.1x, which suggests the market is assigning very little value to any margin rebuild or housing recovery. The right way to own BLDR is not as a clean near-term beat story, because the last quarter included a -13.8% EPS miss and guidance cut, but as a cyclical recovery with meaningful torque if housing stabilizes and cost actions work.
Conviction stays low because leverage is not trivial at 3.84x debt/EBITDA, multifamily remains weak into at least next year, and specialty margins have become less predictable. But at this price, those risks look more recognized than ignored.
Mortgage easing supports starts, multifamily troughs, margins recover toward the top half of guidance, and repurchases amplify EPS rebound.
BLDR executes the $100M cost program, holds share in single-family, and delivers mid-range FY26 EBITDA with modest housing stabilization.
Housing stays weak into 2027, EBITDA tracks near $1.1B, specialty margins do not recover, and leverage constrains buybacks.
Quant call aligns with analyst consensus (Strong Buy: 6 buy / 5 hold / 0 sell).
In the short run, the market is a voting machine, but in the long run, it is a weighing machine.
Forward earnings power is the key debate. The trailing 28.21x P/E looks expensive against peers at 22.1x, but trailing earnings are depressed after FY2025 EPS fell 31.7%, so the real question is whether BLDR can rebuild toward a materially higher mid-cycle earnings base as margins recover from Q1's 5.0% EBITDA margin toward the FY26 guide range of 7.5%-9.6%. The moat is stronger than it was 3 to 5 years ago because BLDR now has broader value-added manufacturing, installed capabilities, digital ordering infrastructure, and 41 acquisitions / $2.3B sales since 2021, but near-term cyclicality is still overpowering that structural progress. AI is more likely to help than hurt, mainly through pricing, network planning, design-to-order workflows, and service productivity on the upcoming digital platform, yet AI will not fix weak starts or multifamily demand. Regulation and mortgage rates matter more than tech here, and with 30-year mortgages at 6.43% and housing starts at 1.18M, down 9% YoY, the recovery path is gradual rather than sharp, which is why the rating stays BUY but conviction stays low.
- Valuation is compressed at 0.55x sales versus peers at 2.1x, with the quant engine's $100.75 target implying 35.2% upside from $74.54.
- Management still expects $14.6B-$15.6B FY26 net sales, $1.1B-$1.5B adjusted EBITDA, and $400M-$500M free cash flow after cutting guidance.
- Capital return remains active, with 3.3M shares repurchased for $303M in Q1 and a refreshed $500M authorization.
- Single-family share growth continued in Q1 even as company net sales fell 10%, showing BLDR is not just riding the cycle but still taking business.
- Management has already launched $100M of cost actions, with $13M realized in Q1 and the actions complete or meaningfully underway, which should help offset weaker volume.
- The stock setup is washed out, -50.6% versus the 52-week high and -65.3% versus the 5-year high, while the business still has $1.5B liquidity and positive Q1 free cash flow of $43M.
- BLDR keeps building value-added scale, with 41 acquisitions adding $2.3B sales since the 2021 merger, and is rolling out a next-gen digital platform later this year with four integrated hubs and embedded AI.
- FY2025 already showed real earnings erosion, with revenue $15.2B, down 5.1%, EPS $3.91, down 31.7%, and operating margin down to 8.7% from 9.7%.
- Q1 FY26 margin deterioration was severe, with adjusted EBITDA margin at 5.0%, down 400 bps YoY and down 130 bps sequentially from Q4's 6.3%.
- Balance sheet flexibility is not pristine for a cyclical distributor-manufacturer, with debt/EBITDA 3.84x, debt/equity 1.32, and a weak internal quality score of 29/100.
- Management explicitly said, "Given the current project pipeline, we don't anticipate a meaningful improvement in our multifamily results until next year," leaving a clear demand hole for the rest of FY26.
| Metric | Value | Context |
|---|---|---|
| Current price | $74.54 | Reference price for the quant target and scenario framing |
| Quant price target | $100.75 | Implies 35.2% upside, Low confidence, basis earnings_growth_blend |
| FY2025 revenue | $15.2B | -5.1% YoY, showing the demand reset is already in the numbers |
| FY2025 EPS | $3.91 | -31.7% YoY, the main reason trailing P/E looks optically high |
| FY2025 operating margin | 8.7% | Down from 9.7% in the prior year |
| Valuation | P/E 28.21x, P/S 0.55x, P/B 2.04x | P/E is above peer avg 22.1x, while P/S is far below peer avg 2.1x |
| Leverage | Debt/EBITDA 3.84x, Debt/Equity 1.32x | Meaningful balance-sheet risk for a cyclical construction exposure |
| FY26 guidance | Sales $14.6B-$15.6B, Adj. EBITDA $1.1B-$1.5B | Guidance was revised lower in Q1 |
| FY26 margin and cash guide | Adj. EBITDA margin 7.5%-9.6%, FCF $400M-$500M | Recovery path depends on cost actions offsetting weak demand |
| Q1 FY26 profitability | Adj. EBITDA $160M, margin 5.0% | Down 400 bps YoY and 130 bps versus Q4's 6.3% |
| Capital return | Buybacks $303M in Q1 | 3.3M shares repurchased, board refreshed authorization to $500M |
| Price position | -50.6% vs 52-week high, -25.4% vs 200-day average | The stock is trading from a heavily de-risked technical setup |
The biggest risk is that FY26 EBITDA lands near the low end of guidance at $1.1B as multifamily stays weak and specialty margins remain volatile, which would leave leverage at an uncomfortable level for a cyclical name with debt/EBITDA of 3.84x.
The next catalyst is Q2 earnings on July 30, 2026, where investors need to see results at least within management's $3.75B-$4.05B sales and $300M-$350M adjusted EBITDA outlook and evidence that the $100M cost program is flowing through.
Ownership is institutionally heavy, with the top three holders at 79.6%, which can support valuation in a recovery but also means sentiment can move fast when estimates reset. Short interest is meaningful at 7.63%, or 7,936,719 shares, though it fell 9.8% and days-to-cover is only 3.1, so this is not an obvious squeeze setup. Near-term options positioning is fragile, with negative gamma and a zero-gamma level at $76.18, just above spot, which can amplify volatility around the July 30 print rather than dampen it.
Revenue fell 5.1% YoY, reflecting lower organic sales and commodity deflation.
Management said single-family share growth continued in Q1 despite softer macro demand.
Still the clearest weak pocket, with management saying no meaningful improvement is expected until next year.
Margins were more challenging, more volatile than expected and contributed to the FY26 guide cut.
Acquisitions and installed/value-added offerings remain the main structural mix upgrade.
BLDR cut FY26 outlook as weaker housing demand and specialty-margin pressure offset share gains.
Management's record is good, but not clean enough for high conviction. From 2024-05-07 through 2025-10-30, BLDR beat EPS in 7 of 8 quarters, including beats of +15.2%, +15.9%, and +7.4%, before missing on 2026-02-17 by -13.8%. The historical 2024 Q2 call already showed management cutting FY24 guidance to $16.4B-$17.2B sales and $2.2B-$2.4B EBITDA while saying, "We think we're around 32% this year. We think our exit rate is around 31% based on everything we're seeing today." Since then, actual FY2025 revenue landed at $15.2B, and FY26 guidance is now down to $14.6B-$15.6B sales with just $1.1B-$1.5B EBITDA and 27.5%-29.0% gross margin. That is a clear miss versus the earlier margin trajectory, but management has at least been directionally honest about multifamily normalization and affordability pressure rather than defending outdated targets. Execution on cost actions and facility consolidation looks credible, but forecasting power on margin durability has weakened materially.
As people discuss, our revised full year guidance reflects these dynamics.
As a result, we are adding net sales in the range of $14.6 billion to $15.6 billion, adjusted EBITDA of $1.1 billion to $1.5 billion and adjusted EBITDA margin of 7.5% to 9.6%.
For Q2, we expect net sales to be between $3.75 billion and $4.05 billion and adjusted EBITDA to be between $300 million and $350 million.
We landed at the upper end of the expected Q1 range for sales and EBITDA even if the macro was worse than we expected.
Given the current project pipeline, we don't anticipate a meaningful improvement in our multifamily results until next year.
BLDR's edge comes from scale, local density, value-added manufacturing, and service reliability. The company kept on-time, in-full delivery above 90% while consolidating 21 facilities YTD after 55 over the prior two years, which is hard for smaller regional players to match. The moat is durable if BLDR keeps deepening its value-added mix and digital integration, but it is not immune to housing cyclicality, which can swamp pricing and mix benefits for several quarters at a time.
Capital allocation has historically been aggressive, especially on buybacks, and that remains true even in a weaker year. BLDR repurchased 3.3M shares for $303M in Q1 and refreshed authorization to $500M, with no dividend and ongoing tuck-in M&A, including Premium Building Components in January. The concern is that FY2025 reported FCF was $0.0B and leverage is 3.84x debt/EBITDA, so continued repurchases need to be paced against the cycle rather than treated as automatic.
BLDR rates BUY with Low conviction. The stock has already absorbed a brutal reset, and at $74.54 the downside case is no longer being ignored by the market. The reason to own it is a recovery in earnings power from a cyclical trough, helped by $100M of cost actions, continued single-family share gains, and opportunistic buybacks. The reason not to overreach is that margins are still falling, leverage is elevated, and management just cut guidance. A move to HOLD would require either a sharp rally without earnings improvement or another material guide-down that puts FY26 EBITDA near the $1.1B floor with no sign of stabilization.
≣ Full research note tap to expand
Executive Summary
BUY, Low conviction. Rated BUY, Low conviction. The stock is down 50.6% from its 52-week high and sits 25.4% below its 200-day average, while management still guides to $1.1B-$1.5B FY26 adjusted EBITDA and $400M-$500M free cash flow despite a weak housing backdrop. The case is not about clean near-term momentum, it is about paying 0.55x sales for a scaled platform that is still taking single-family share, cutting costs, and buying back stock into a cyclical trough.
Investment Thesis
BLDR is being priced like a business with no credible recovery path. That goes too far. At $74.54, the stock reflects a sharp de-rating after a real earnings reset, with shares 50.6% below the 52-week high and 25.4% below the 200-day average. The underlying business is clearly under pressure, but it is not broken. BLDR still generated $15.2B of FY2025 revenue, remains profitable at an 8.7% operating margin, and is guiding to $1.1B-$1.5B of FY26 adjusted EBITDA even after cutting outlook. For a company with scale, value-added manufacturing, installed capabilities, and ongoing share gains in single-family, that setup is more trough-like than terminal.
The case depends on three things. First, margins need to stop falling. Q1's 5.0% EBITDA margin was weak, with gross margin down 220 bps, but management has already launched $100M of cost actions and realized $13M in Q1. Second, BLDR needs to keep taking share where demand still exists. Management said single-family share growth continued even as macro conditions worsened, which matters because it shows BLDR's operating model is still winning accounts in a shrinking market. Third, capital allocation has to stay disciplined enough to turn cyclical weakness into per-share upside. Repurchasing 3.3M shares for $303M at depressed prices helps, but only if leverage remains manageable.
What the market may be missing is the gap between current earnings and normalized earnings power. The headline 28.21x P/E looks expensive, but that is a bad lens when FY2025 EPS dropped 31.7% and margin pressure is still moving through the model. On sales, the stock is at just 0.55x, far below the peer average 2.1x, which suggests the market is assigning very little value to any margin rebuild or housing recovery. The right way to own BLDR is not as a clean near-term beat story, because the last quarter included a -13.8% EPS miss and guidance cut, but as a cyclical recovery with meaningful torque if housing stabilizes and cost actions work.
Conviction stays low because leverage is not trivial at 3.84x debt/EBITDA, multifamily remains weak into at least next year, and specialty margins have become less predictable. But at this price, those risks look more recognized than ignored.
Key Metrics
| Metric | Value | Context |
|---|---|---|
| Current price | $74.54 | Reference price for the quant target and scenario framing |
| Quant price target | $100.75 | Implies 35.2% upside, Low confidence, basis earnings_growth_blend |
| FY2025 revenue | $15.2B | -5.1% YoY, showing the demand reset is already in the numbers |
| FY2025 EPS | $3.91 | -31.7% YoY, the main reason trailing P/E looks optically high |
| FY2025 operating margin | 8.7% | Down from 9.7% in the prior year |
| Valuation | P/E 28.21x, P/S 0.55x, P/B 2.04x | P/E is above peer avg 22.1x, while P/S is far below peer avg 2.1x |
| Leverage | Debt/EBITDA 3.84x, Debt/Equity 1.32x | Meaningful balance-sheet risk for a cyclical construction exposure |
| FY26 guidance | Sales $14.6B-$15.6B, Adj. EBITDA $1.1B-$1.5B | Guidance was revised lower in Q1 |
| FY26 margin and cash guide | Adj. EBITDA margin 7.5%-9.6%, FCF $400M-$500M | Recovery path depends on cost actions offsetting weak demand |
| Q1 FY26 profitability | Adj. EBITDA $160M, margin 5.0% | Down 400 bps YoY and 130 bps versus Q4's 6.3% |
| Capital return | Buybacks $303M in Q1 | 3.3M shares repurchased, board refreshed authorization to $500M |
| Price position | -50.6% vs 52-week high, -25.4% vs 200-day average | The stock is trading from a heavily de-risked technical setup |
Financial Strength
Financial strength is adequate, not robust. BLDR still has scale, positive earnings, $1.5B of liquidity, and guided FY26 free cash flow of $400M-$500M, which matters in a downturn. But the balance sheet is carrying real cyclical risk with $5.3B of debt and 3.84x debt/EBITDA, while FY2025 reported free cash flow was $0.0B and profitability has compressed from a much higher prior-cycle level. This is a company that can survive the trough, not one that can ignore it.
Competitive Position
BLDR's edge comes from scale, local density, value-added manufacturing, and service reliability. The company kept on-time, in-full delivery above 90% while consolidating 21 facilities YTD after 55 over the prior two years, which is hard for smaller regional players to match. The moat is durable if BLDR keeps deepening its value-added mix and digital integration, but it is not immune to housing cyclicality, which can swamp pricing and mix benefits for several quarters at a time.
Management & Guidance
Management cut FY26 outlook and deserves to be taken seriously because the reduction was backed by specifics, not hand-waving. As CFO Pete Beckmann said, "As a result, we are adding net sales in the range of $14.6 billion to $15.6 billion, adjusted EBITDA of $1.1 billion to $1.5 billion and adjusted EBITDA margin of 7.5% to 9.6%." The near-term test is Q2, where the company guided to $3.75B-$4.05B of sales and $300M-$350M of adjusted EBITDA, while management also stressed, "We landed at the upper end of the expected Q1 range for sales and EBITDA even if the macro was worse than we expected." That supports moderate credibility on execution, but not enough to dismiss the very visible pressure in multifamily and specialty margins.
Segment Analysis
- Total company ($15.2B FY2025 revenue): Revenue fell 5.1% YoY, reflecting lower organic sales and commodity deflation.
- Single-family exposure (Not disclosed): Management said single-family share growth continued in Q1 despite softer macro demand.
- Multifamily exposure (Not disclosed): Still the clearest weak pocket, with management saying no meaningful improvement is expected until next year.
- Specialty products (Not disclosed): Margins were more challenging, more volatile than expected and contributed to the FY26 guide cut.
- Value-added and acquired businesses ($2.3B acquired sales since 2021): Acquisitions and installed/value-added offerings remain the main structural mix upgrade.
Capital Allocation
Capital allocation has historically been aggressive, especially on buybacks, and that remains true even in a weaker year. BLDR repurchased 3.3M shares for $303M in Q1 and refreshed authorization to $500M, with no dividend and ongoing tuck-in M&A, including Premium Building Components in January. The concern is that FY2025 reported FCF was $0.0B and leverage is 3.84x debt/EBITDA, so continued repurchases need to be paced against the cycle rather than treated as automatic.
Management Execution & Track Record
Management's record is good, but not clean enough for high conviction. From 2024-05-07 through 2025-10-30, BLDR beat EPS in 7 of 8 quarters, including beats of +15.2%, +15.9%, and +7.4%, before missing on 2026-02-17 by -13.8%. The historical 2024 Q2 call already showed management cutting FY24 guidance to $16.4B-$17.2B sales and $2.2B-$2.4B EBITDA while saying, "We think we're around 32% this year. We think our exit rate is around 31% based on everything we're seeing today." Since then, actual FY2025 revenue landed at $15.2B, and FY26 guidance is now down to $14.6B-$15.6B sales with just $1.1B-$1.5B EBITDA and 27.5%-29.0% gross margin. That is a clear miss versus the earlier margin trajectory, but management has at least been directionally honest about multifamily normalization and affordability pressure rather than defending outdated targets. Execution on cost actions and facility consolidation looks credible, but forecasting power on margin durability has weakened materially.
Positioning & Flows
Ownership is institutionally heavy, with the top three holders at 79.6%, which can support valuation in a recovery but also means sentiment can move fast when estimates reset. Short interest is meaningful at 7.63%, or 7,936,719 shares, though it fell 9.8% and days-to-cover is only 3.1, so this is not an obvious squeeze setup. Near-term options positioning is fragile, with negative gamma and a zero-gamma level at $76.18, just above spot, which can amplify volatility around the July 30 print rather than dampen it.
Bull Case
- Single-family share growth continued in Q1 even as company net sales fell 10%, showing BLDR is not just riding the cycle but still taking business.
- Management has already launched $100M of cost actions, with $13M realized in Q1 and the actions complete or meaningfully underway, which should help offset weaker volume.
- The stock setup is washed out, -50.6% versus the 52-week high and -65.3% versus the 5-year high, while the business still has $1.5B liquidity and positive Q1 free cash flow of $43M.
- BLDR keeps building value-added scale, with 41 acquisitions adding $2.3B sales since the 2021 merger, and is rolling out a next-gen digital platform later this year with four integrated hubs and embedded AI.
Bear Case
- FY2025 already showed real earnings erosion, with revenue $15.2B, down 5.1%, EPS $3.91, down 31.7%, and operating margin down to 8.7% from 9.7%.
- Q1 FY26 margin deterioration was severe, with adjusted EBITDA margin at 5.0%, down 400 bps YoY and down 130 bps sequentially from Q4's 6.3%.
- Balance sheet flexibility is not pristine for a cyclical distributor-manufacturer, with debt/EBITDA 3.84x, debt/equity 1.32, and a weak internal quality score of 29/100.
- Management explicitly said, "Given the current project pipeline, we don't anticipate a meaningful improvement in our multifamily results until next year," leaving a clear demand hole for the rest of FY26.
Valuation & Price Target
Engine price target $100.75 (+35.2% vs current), Low confidence.
- P/E Multiple: $41.85 (28% weight)
- P/S Multiple: $218.24 (20% weight)
- Quality-adjusted: $62.02 (20% weight)
- DCF: $111.92 (7% weight)
The rating matches the quant baseline at BUY, but only at Low conviction because the quality profile is weak at 29/100, peer-based valuation inputs are noisy, and BLDR currently trades on depressed but unstable earnings. The engine's $100.75 target is plausible because the stock is already down 50.6% from the 52-week high and the company still guides to up to $1.5B EBITDA and $500M FCF, yet the wide peer P/E dispersion at 3.1x and BLDR's own trailing 28.21x P/E argue against a stronger call. Sell-side consensus is broadly positive, but that is low-signal context here; the real support for BUY is the reset price, cost actions, and mid-cycle earnings recovery potential, not consensus.
Risk Assessment
Risk score 62/100 (Moderate). The biggest risk is that FY26 EBITDA lands near the low end of guidance at $1.1B as multifamily stays weak and specialty margins remain volatile, which would leave leverage at an uncomfortable level for a cyclical name with debt/EBITDA of 3.84x.
The Bottom Line
BLDR rates BUY with Low conviction. The stock has already absorbed a brutal reset, and at $74.54 the downside case is no longer being ignored by the market. The reason to own it is a recovery in earnings power from a cyclical trough, helped by $100M of cost actions, continued single-family share gains, and opportunistic buybacks. The reason not to overreach is that margins are still falling, leverage is elevated, and management just cut guidance. A move to HOLD would require either a sharp rally without earnings improvement or another material guide-down that puts FY26 EBITDA near the $1.1B floor with no sign of stabilization.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr